Dark

ABEO
Abeona Therapeutics Inc. Common Stock
stock NASDAQ

At Close

Jul 17, 2026 3:59:57 PM EDT

6.99USD-0.356%(-0.03)777,459

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jul 17, 2026 9:02:30 AM EDT

6.94USD-1.140%(-0.08)12,401

After-hours

Jul 17, 2026 4:00:30 PM EDT

7.00USD+0.071%(+0.01)68,748

OverviewOptionsHistoricalExchangesShortsNews

Dec 22, 2021

07:34AM EST Abeona Therapeutics Issues Letter To Shareholders Benzinga

07:30AM EST Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to shareholders. GlobeNewswire Inc

Dec 17, 2021

02:47PM EST Mid-Afternoon Market Update: Crude Oil Drops Over 2%; Bottomline Technologies Shares Spike Higher Benzinga

12:05PM EST Mid-Day Market Update: Dow Tumbles 500 Points; Abeona Therapeutics Shares Plummet Benzinga

09:02AM EST Abeona Therapeutics Prices 44.7M Share Offering Of Stock, Warrants At $0.39/Unit Benzinga

09:00AM EST Abeona Therapeutics Announces Pricing of Public Offering of Common GlobeNewswire Inc

Dec 16, 2021

04:02PM EST Abeona Therapeutics Reports Offering Of Common Stock, No Size Disclosed Benzinga

04:01PM EST Abeona Therapeutics Announces Public Offering of Common Stock and GlobeNewswire Inc

Nov 30, 2021

04:51PM EST Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021 Benzinga

04:42PM EST SVB Leerink Downgrades Abeona Therapeutics to Market Perform, Lowers Price Target to $1 Benzinga

Nov 29, 2021

07:29AM EST 10 Biggest Price Target Changes For Monday Benzinga

06:11AM EST HC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Lowers Price Target to $4 Benzinga

Nov 23, 2021

08:10AM EST The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug Benzinga

Nov 21, 2021

03:05PM EST The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week Benzinga

Nov 18, 2021

07:30AM EST Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its sponsorship of the second annual Venture Into Cures, a virtual event supporting EB Research Partnership's mission to find a cure for epidermolysis bullosa (EB). The event will take place virtually on November 18, 2021 at 8:00 p.m. ET/ 5:00 p.m. PT. GlobeNewswire Inc

Nov 17, 2021

07:30AM EST Abeona Therapeutics Announces Presentation on Pivotal Transpher A GlobeNewswire Inc

Nov 16, 2021

07:30AM EST Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chief Executive Officer of Abeona, will participate virtually in a fireside chat at the Jefferies London Healthcare Conference being held November 16-19, 2021. GlobeNewswire Inc

Nov 15, 2021

10:59AM EST Abeona Therapeutics Q3 EPS $(0.07) Up From $(0.08) YoY Benzinga

07:45AM EST Phase 3 VIITAL study on track to complete enrollment in first quarter 2022 with final patients identified and under screening GlobeNewswire Inc

Oct 21, 2021

12:11PM EDT The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO Benzinga

12:11PM EDT Abeona Therapeutics To Present At Jefferies Gene Therapy/Editing Summit Benzinga

07:30AM EDT Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., M.B.A., Chief Executive Officer of Abeona, is scheduled to present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021, at 3:30 p.m. ET. GlobeNewswire Inc

Oct 18, 2021

07:34AM EDT The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs Benzinga

Oct 13, 2021

01:38PM EDT Abeona Therapeutics Announces Clinical Data Presentations At Upcoming Scientific Congresses Benzinga

07:30AM EDT Abeona Therapeutics Announces Clinical Data Presentations at GlobeNewswire Inc

Oct 12, 2021

07:30AM EDT Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Jon Voss as Vice President, Head of Quality. Mr. Voss, who has been advising the Company as a consultant, will now serve in a leadership role to further strengthen Abeonas quality system and oversee all quality functions. GlobeNewswire Inc

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Sep 22, 2021

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Sep 21, 2021

04:02PM EDT Abeona Announces Steven H. Rouhandeh To Retire As Chairman Of The Board And Michael Amoroso Appointed Chairman Of The Board; Vishwas Seshadri, Ph.D., M.B.A. To Become Chief Executive Officer Benzinga

04:01PM EDT Steven H. Rouhandeh to retire as Chairman of the Board; Michael Amoroso appointed Chairman of the Board GlobeNewswire Inc

Sep 7, 2021

07:30AM EDT Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the companys management will present and conduct one-on-one meetings at the following virtual investor conferences: GlobeNewswire Inc

Aug 10, 2021

09:28AM EDT Abeona Therapeutics Appoints Edward Carr As CFO RTTNews

07:30AM EDT Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr as Chief Financial Officer and Principal Financial Officer, effective immediately. Mr. Carr had served as Abeonas Chief Accounting Officer since January 2019. GlobeNewswire Inc

Jul 28, 2021

04:09PM EDT Abeona Therapeutics Q2 EPS $(0.16) Down From $(0.14) YoY Benzinga

04:01PM EDT Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL study GlobeNewswire Inc

10:53AM EDT Abeona Stock Gains As It Concludes Type B Meeting With FDA For MPS IIIA Gene Therapy Benzinga

07:32AM EDT UPDATE: Abeona Says Aligned With FDA On ABO-102 Primary Endpoint For Study Benzinga

07:32AM EDT Abeona Therapeutics Reports Completed Type B Meeting With FDA For ABO-102 Gene Therapy In Sanfilippo Syndrome Type A Benzinga

07:30AM EDT Transpher A; pivotal study for intended registration of ABO-102 for MPS IIIA disease GlobeNewswire Inc

Jul 26, 2021

01:54PM EDT Abeona Therapeutics shares were trading higher after the company announced new MRI data showing increased brain volume in young patients with Sanfilippo Syndrome Type A after treatment with ABO-102 gene therapy. Benzinga

07:35AM EDT Abeona Therapeutics Announces Data From its Phase 1/2 Clinical Study Indicating its ABO-102 Increased Grey Matter, Corpus Callosum and Amygdala Volumes in the Brain in Three Young Patients with Sanfilippo Syndrome Benzinga

07:30AM EDT Abeona Therapeutics Announces New MRI Data Showing Increased Brain GlobeNewswire Inc

Jul 23, 2021

07:36AM EDT Abeona Therapeutics Activates Second Clinical Trial Site In EB-101 Pivotal Phase 3 VIITAL Study For Recessive Dystrophic Epidermolysis Bullosa Benzinga

07:30AM EDT Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical trial site in its pivotal Phase 3 VIITAL study of its investigational EB-101 treatment for recessive dystrophic epidermolysis bullosa (RDEB) at UMass Memorial Medical Center in Worcester, MA. GlobeNewswire Inc

Jul 19, 2021

07:47AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:42AM EDT HC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Lowers Price Target to $5 Benzinga

Jul 7, 2021

12:02PM EDT Abeona Unveils Additional Data From Gene Therapy Trial For Rare Connective Tissue Disorder Benzinga

07:33AM EDT Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results In Recessive Dystrophic Epidermolysis Bullosa At The Society For Pediatric Dermatology 46th Annual Meeting Benzinga

07:30AM EDT Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical GlobeNewswire Inc

Jun 7, 2021

03:35PM EDT Abeona Therapeutics Files For Mixed Shelf Offering Of Up To $250M Benzinga

Jun 2, 2021

07:30AM EDT Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 a.m. ET. GlobeNewswire Inc

May 26, 2021

07:42AM EDT Abeona Therapeutics In Stockholder Letter Says Expect To Complete Patient Enrollment In Viital Study In 2021 And Anticipate Top-line Data In Mid-2022 Benzinga

07:30AM EDT Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today issued the following letter to stockholders in conjunction with the 2021 Abeona Therapeutics Annual Meeting of Stockholders to be held today, May 26, 2021: GlobeNewswire Inc

May 25, 2021

07:30AM EDT Abeona Therapeutics Appoints Head of Research & Clinical Development GlobeNewswire Inc

May 18, 2021

07:37AM EDT Abeona Therapeutics Q1 Loss Per Share $0.17 Vs Loss $0.52 Last Year RTTNews

07:32AM EDT Abeona Therapeutics Q1 EPS $(0.17) Up From $(0.52) YoY Benzinga

07:30AM EDT Patient enrollment ongoing for EB-101 pivotal Phase 3 VIITAL study GlobeNewswire Inc

Apr 20, 2021

07:40AM EDT Abeona Therapeutics To Highlight New Data From Preclinical Research At Association For Research In Vision And Ophthalmology 2021 Annual Meeting May 1-7 Benzinga

07:30AM EDT Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that new data from its preclinical research will be highlighted during an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, being held virtually from May 1-7, 2021. GlobeNewswire Inc

Apr 19, 2021

07:30AM EDT Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Dr. Leila Alland and Mr. Donald Wuchterl as new independent members to its Board of Directors. GlobeNewswire Inc

Mar 25, 2021

07:30AM EDT Abeona Therapeutics Announces Appointment of Two New Independent GlobeNewswire Inc

Mar 24, 2021

04:04PM EDT Abeona Therapeutics Q4 EPS $(0.17) Up From $(0.30) YoY, Sales $3.00M Benzinga

04:01PM EDT Fourth patient treated in pivotal Phase 3 VIITAL study of EB-101 in RDEB after successful Type B meeting with FDA GlobeNewswire Inc

Mar 22, 2021

07:42AM EDT Abeona Therapeutics Inc. (ABEO) announced the promotion of Michael Amoroso, Executive Vice President, Chief Operating Officer, to President, Chief Executive Officer and a member of the Board, effective immediately. Most recently, Amoroso has been responsible for overseeing the operational management of Abeona and business development as COO and principal executive officer. RTTNews

07:38AM EDT Abeona Therapeutics Appoints Michael Amoroso As CEO RTTNews

07:31AM EDT Abeona Therapeutics Announces Michael Amoroso CEO Benzinga

07:30AM EDT Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, Executive Vice President, Chief Operating Officer (COO) and principal executive officer at Abeona, has been promoted to President, Chief Executive Officer (CEO) and a member of the companys Board of Directors, effective immediately. GlobeNewswire Inc

Feb 22, 2021

07:30AM EST Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the company will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 11:20 am EST. GlobeNewswire Inc

Feb 12, 2021

11:36AM EST In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained reductions in disease-specific biomarkers, denoting clear biologic effects GlobeNewswire Inc

Feb 6, 2021

12:42PM EST The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Benzinga

Feb 2, 2021

07:39AM EST Abeona Therapeutics Reports Clinical Investigator Webinar To Review ABO-102, ABO-101 Data Presented AT WORLDSymposium Tuesday, Feb. 16, 2021 At 1 p.m. EST Benzinga

07:30AM EST Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it will host a live webinar for the investment community on Tuesday, February 16, 2021 at 1:00 p.m. EST to review clinical data on the companys investigational AAV-based gene therapies ABO-102 and ABO-101 presented at the 17th Annual WORLDSymposium. GlobeNewswire Inc

Jan 25, 2021

07:50AM EST Abeona Announces Successful Type B Meeting With FDA For Pivotal Phase 3 VIITAL Study Of EB-101 RTTNews

07:32AM EST Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa Benzinga

07:30AM EST Abeona Therapeutics Announces Successful Type B Meeting with FDA GlobeNewswire Inc

Dec 21, 2020

12:20PM EST Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts GlobeNewswire Inc

Nov 25, 2020

08:01AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

06:19AM EST HC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Lowers Price Target to $8 Benzinga

Nov 11, 2020

09:53AM EST Benzinga's Top Upgrades, Downgrades For November 11, 2020 Benzinga

05:48AM EST Cantor Fitzgerald Upgrades Abeona Therapeutics to Overweight, Announces $4 Price Target Benzinga

Nov 10, 2020

11:32AM EST SVB Leerink Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $5 Benzinga

Nov 9, 2020

04:30PM EST Abeona Therapeutics Q3 EPS $(0.08) Up From $(0.35) YoY Benzinga

04:05PM EST Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced financial results for the third quarter 2020 and recent business progress. GlobeNewswire Inc

Nov 4, 2020

08:21AM EST The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings Benzinga

Oct 27, 2020

07:50AM EDT Abeona Therapeutics Announces The Appointment Of Michael Amoroso As Chief Operating Officer Benzinga

06:30AM EDT Abeona Therapeutics Announces the Appointment of Michael Amoroso GlobeNewswire Inc

Oct 6, 2020

04:02PM EDT Abeona Therapeutics Names Steven Rouhandeh Chair; Co. Has Retained Jefferies As Financial Advisor To Assist With Strategic Options Review Benzinga

04:01PM EDT Abeona Therapeutics Board of Directors Forms GlobeNewswire Inc

Sep 28, 2020

04:10PM EDT Why Abeona's Stock Is Trading Lower Today Benzinga

09:28AM EDT Abeona Therapeutics Announces Joo Siffert Resigned As CEO, Head Of R&D, CMO, Board Member On Sept. 23 Benzinga

09:27AM EDT Abeona Therapeutics Announces Leadership and Board Transitions GlobeNewswire Inc

Sep 18, 2020

11:09AM EDT Why Abeona Therapeutics Is Trading Higher Today Benzinga

09:31AM EDT Benzinga's Top Upgrades, Downgrades For September 18, 2020 Benzinga

08:33AM EDT B. Riley FBR Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $5 Benzinga

Sep 8, 2020

04:05PM EDT Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company will participate in the following upcoming investor conferences. GlobeNewswire Inc

Aug 17, 2020

07:10AM EDT Abeona Therapeutics And Taysha Gene Therapies Enter Licensing And Inventory Purchase Agreements For ABO-202 RTTNews

07:02AM EDT UPDATE: Taysha To Make Initial Cash Payments Of $7M To Abeona; Abeona Is Eligible To Receive Up To $56M Upon Achievement Of Milestones Benzinga

07:01AM EDT Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202 Gene Therapy for CLN1 Disease Benzinga

07:00AM EDT Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing GlobeNewswire Inc

Aug 10, 2020

04:17PM EDT Abeona Therapeutics Q2 EPS $(0.14) Up From $(0.49) YoY Benzinga

04:01PM EDT Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs GlobeNewswire Inc